Health Benefits of Bimuno GOS

Scientifically validated prebiotic action for multiple health applications

Bimuno® GOS is clinically shown to selectively stimulate Bifidobacteria and Lactobacilli, supporting key health benefits in both humans and animals.

The science of selective prebiotic action

Unlike other commercial prebiotics that may be metabolised by various microbes, Bimuno GOS stands out for its high selectivity by specific beneficial bacteria, including bifidobacteria and lactobacilli. Its unique structure, including specific beta-linkages and a characteristic degree of polymerisation, drives its scientifically validated functionality.

 

A key component, 3-galactosyl-lactose, is a human milk oligosaccharide (HMO) recognised as a preferred food source for bifidobacteria. This structural advantage helps explain why Bimuno GOS consistently shows strong bifidogenic effects and health benefits in clinical studies.

Research-backed efficacy

Bimuno GOS delivers clinically validated benefits at a low daily dose of just 1.37g – with results observed in as little as 7 days in multiple studies.

 

Recent groundbreaking research shows that bifidogenic effects can begin at doses as low as 380mg. While the 1.37g dose remains associated with our core clinically proven benefits, this ultra-low dose flexibility offers significant advantages for applications where space is limited, such as capsules and tablets

Partnering for health innovation

Building the future of health products starts with working with ingredients that are trusted by science and by consumers. At Clasado, we work alongside brands and formulators to turn cutting-edge microbiome research into commercially successful products – from concept to shelf.